[Asia Economy Reporter Hyunseok Yoo] GenCurix, a liquid biopsy molecular diagnostics specialist company, announced on the 6th that it has finally registered a US patent for Methods for predicting risk of recurrence of breast cancer patients.
The patent pertains to the biomarker and algorithm technology of Jinswell BCT, independently developed by GenCurix. Prior to this US patent registration, the patent was registered domestically in September 2018, and individual country patent examinations are underway in China, Europe, Japan, and other regions.
A GenCurix official stated, "We are securing patents in major overseas countries not only to maintain Jinswell BCT's number one position in the domestic market but also to enter the global market. Especially by proving our technology in the US, which has the largest breast cancer prognosis diagnosis market, our global market strategy will gain more momentum."
He added, "We will acquire additional patents in China, Japan, and Europe to widely promote the world-class technology of GenCurix diagnostic products and expand our global presence."
Jinswell BCT is the first and only breast cancer prognosis diagnostic test in Asia to receive official approval from national institutions. Numerous clinical trials have demonstrated that patients classified as low-risk through the test show high survival rates regardless of chemotherapy. The number of general hospitals that have completed coding and can directly prescribe the test is rapidly increasing from the fourth quarter of this year, so meaningful domestic sales are expected next year.
Along with this, the company is actively expanding its global distributor network. Following participation in MEDICA, the largest medical device exhibition in Europe, last November, it is preparing to participate in Arab Health in January next year. Previously, the company signed a local distributor supply contract for Jinswell BCT with Neogen Diagnostik, a diagnostic device distributor in Turkey and Eastern Europe.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

